公开(公告)号：US08017652B2

公开(公告)日：2011-09-13

申请号：US12463197

申请日：2009-05-08

Applicant: Yoshihiro Shidoji ,  Naoto Ishibashi

Inventor： Yoshihiro Shidoji ,  Naoto Ishibashi

IPC: A61K31/20

CPC classification number: A61K31/20 ,  A61K31/202 ,  Y10S514/866

Abstract: Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14 -hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient.

Abstract translation: 过氧化物酶体增殖物激活受体的活化剂，其包含聚异戊二烯基化合物，优选（2E，4E，6E，10E）-3,7,11,15-四甲基-2,4,6,10,14-十六碳五烯酸作为活性成分 以及用于预防和/或治疗高脂血症的药物，非胰岛素依赖性糖尿病等，其包含聚异戊二烯基化合物作为活性成分。

公开(公告)号：US08017329B2

公开(公告)日：2011-09-13

申请号：US12751307

申请日：2010-03-31

Applicant: Tsutomu Takeuchi ,  Kensei Tsuzaka ,  Keiko Yoshimoto

Inventor： Tsutomu Takeuchi ,  Kensei Tsuzaka ,  Keiko Yoshimoto

IPC: C12Q1/68

CPC classification number: C07K16/2875 ,  A61K31/341 ,  G01N33/5008 ,  G01N33/5023 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/6863 ,  G01N2500/00

Abstract: A method of screening a novel BAFF suppressor or inhibitor. More specifically speaking, a method which comprises adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell to thereby induce the production of BAFF by the cell; a method of screening a substance capable of suppressing the expression or activity of BAFF which comprises adding a test substance to a BAFF-production system prepared by adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell and measuring the expression amount and/or the activity of BAFF in the BAFF-production system; and a BAFF production inducer for a BAFF-producing cell which contains a combination of TPA with ionomycin and/or an anti-CD3 antibody.

Abstract translation: 筛选新型BAFF抑制剂或抑制剂的方法。 更具体地说，包括将TPA与离子霉素和/或抗CD3抗体的组合加入到培养的人细胞中，从而诱导细胞产生BAFF的方法; 筛选能够抑制BAFF的表达或活性的物质的方法，其包括向经培养的人细胞添加TPA与离子霉素和/或抗CD3抗体的组合而制备的BAFF-生产系统中的测试物质，以及 测量BAFF在BAFF生产系统中的表达量和/或活性; 以及含有TPA与离子霉素和/或抗CD3抗体的组合的BAFF产生细胞的BAFF产生诱导剂。

公开(公告)号：US08012989B2

公开(公告)日：2011-09-06

申请号：US12815905

申请日：2010-06-15

Applicant: Tadaaki Ohgiya ,  Toru Miura ,  Ayumu Okuda ,  Toshiharu Arai ,  Koichi Yamazaki ,  Taro Aoki ,  Katsutoshi Miyosawa ,  Haruki Shibata ,  Kimiyuki Shibuya

Inventor： Tadaaki Ohgiya ,  Toru Miura ,  Ayumu Okuda ,  Toshiharu Arai ,  Koichi Yamazaki ,  Taro Aoki ,  Katsutoshi Miyosawa ,  Haruki Shibata ,  Kimiyuki Shibuya

IPC: A61K31/505

CPC classification number: C07D401/12 ,  C07D403/12 ,  C07D471/04

Abstract: A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7 and R8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R10 and R11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

Abstract translation: 由下列通式（I）表示的化合物，其中R 1，R 2，R 3，R 4和R 5表示氢原子，卤原子，低级烷基等，R 6表示烷基，环烷基等 ，R7和R8表示氢原子，低级烷基，（低级环烷基）（低级烷基）等，R9表示氢原子，卤素原子，低级烷氧基等，R10和R11表示氢原子 ，低级烷基，低级烷氧基，卤代（低级烷基）等，A表示6〜10个原子构成的杂环，对胆固醇酯转移蛋白（CETP）具有有效的抑制活性。

公开(公告)号：US08008306B2

公开(公告)日：2011-08-30

申请号：US12430397

申请日：2009-04-27

Applicant: Minoru Koura ,  Ayumu Okuda ,  Takayuki Matsuda ,  Yuki Yamaguchi ,  Hisashi Sumida ,  Sayaka Kurobuchi ,  Yuichiro Watanabe ,  Takashi Enomoto ,  Kimiyuki Shibuya

Inventor： Minoru Koura ,  Ayumu Okuda ,  Takayuki Matsuda ,  Yuki Yamaguchi ,  Hisashi Sumida ,  Sayaka Kurobuchi ,  Yuichiro Watanabe ,  Takashi Enomoto ,  Kimiyuki Shibuya

IPC: C07D215/12 ,  C07D215/233 ,  C07D241/40 ,  A61K31/4709 ,  A61K31/498

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D405/14

Abstract: To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate.

Abstract translation: 提供一种新颖的LXR＆bgr 可用作动脉粥样硬化的预防和/或治疗剂的激动剂; 动脉硬化，如糖尿病引起的; 血脂异常 高胆固醇血症 脂质相关疾病; 由炎性细胞因子引起的炎性疾病; 皮肤病如过敏性皮肤病; 糖尿病; 或阿尔茨海默病。 由以下通式（1）表示的喹啉化合物或其盐或其溶剂化物。

公开(公告)号：US07919509B2

公开(公告)日：2011-04-05

申请号：US12394548

申请日：2009-02-27

Applicant: Ayumu Okuda ,  Takayuki Matsuda ,  Toru Miura ,  Hidefumi Ozawa ,  Ayako Tosaka ,  Koichi Yamazaki ,  Yuki Yamaguchi ,  Sayaka Kurobuchi ,  Yuichiro Watanabe ,  Kimiyuki Shibuya

Inventor： Ayumu Okuda ,  Takayuki Matsuda ,  Toru Miura ,  Hidefumi Ozawa ,  Ayako Tosaka ,  Koichi Yamazaki ,  Yuki Yamaguchi ,  Sayaka Kurobuchi ,  Yuichiro Watanabe ,  Kimiyuki Shibuya

IPC: A61K31/4166 ,  A61K31/427 ,  A61K31/45 ,  A61K31/422 ,  A61K31/4525 ,  C07D405/12 ,  C07D417/12 ,  C07D413/12 ,  C07D407/12

CPC classification number: C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12

Abstract: To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.[Solving Means] A 2-oxochromene derivative represented by the following general formula (1) or salt thereof, or their solvate.

Abstract translation: 提供一种新颖的LXR＆bgr 可用作动脉粥样硬化的预防和/或治疗剂的激动剂; 动脉硬化，如糖尿病引起的; 血脂异常 高胆固醇血症 脂质相关疾病; 由炎性细胞因子引起的炎性疾病; 皮肤病如过敏性皮肤病; 糖尿病; 或阿尔茨海默病。 [解决方案]由以下通式（1）表示的2-氧代色烯衍生物或其盐或其溶剂合物。

公开(公告)号：US20100324091A1

公开(公告)日：2010-12-23

申请号：US12666015

申请日：2008-06-23

Applicant: Noriaki Gomi ,  Shinji Ina ,  Kenjirou Yamana ,  Yoshio Kaneko

Inventor： Noriaki Gomi ,  Shinji Ina ,  Kenjirou Yamana ,  Yoshio Kaneko

IPC: A61K31/454 ,  C07D231/20 ,  A61K31/4152 ,  C07D401/06 ,  A61P7/02

CPC classification number: C07D231/20 ,  C07D231/22 ,  C07D401/06 ,  C07D405/12

Abstract: A pyrazolone derivative represented by formula (I) below: wherein R1 to R3 are the same as defined in claims; or an optical isomer, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is provided. The novel pyrazolone derivative according to the present invention has a PAI-1 production inhibitory activity, a tissue fibrosis inhibitory activity, and a fibrolytic activity, and is effective for preventing and/or treating tissue fibrotic diseases (lung fibrosis, kidney fibrosis, etc.) and diseases of which a pathological thrombus becomes the cause, such as ischemic cardiac diseases (cardiac infarction and angina pectoris), atrial thrombus, lung embolism, deep thrombophlebitis, disseminated intravascular clotting, ischemic brain diseases (brain infarction, brain hemorrhage), and arterial sclerosis. In addition, a pharmaceutical agent for preventing and/or treating the disease conditions or the symptoms mediated by plasminogen activator inhibitor-1, comprising the novel pyrazolone derivative according to the present invention is also provided.

Abstract translation: 由下式（I）表示的吡唑啉酮衍生物：其中R1至R3与权利要求中所定义相同; 或光学异构体，其药学上可接受的盐，或其水合物或溶剂化物。 根据本发明的新型吡唑啉酮衍生物具有PAI-1产生抑制活性，组织纤维化抑制活性和纤维分解活性，对预防和/或治疗组织纤维化疾病（肺纤维化，肾纤维化等）有效 ）和病理性血栓成为原因的疾病，如缺血性心脏病（心肌梗死和心绞痛），心房血栓，肺栓塞，深部血栓性静脉炎，弥漫性血管内凝血，缺血性脑病（脑梗死，脑出血）等） 动脉硬化。 此外，还提供了包含根据本发明的新型吡唑啉酮衍生物的用于预防和/或治疗疾病状况或由纤溶酶原激活物抑制剂-1介导的症状的药剂。

公开(公告)号：US20100280013A1

公开(公告)日：2010-11-04

申请号：US12769104

申请日：2010-04-28

Applicant: Minoru Koura ,  Hisashi Sumida ,  Sayaka Kurobuchi ,  Takayuki Matsuda ,  Yuichiro Watanabe ,  Takashi Enomoto ,  Kimiyuki Shibuya ,  Sumiko Kurobuchi

Inventor： Minoru Koura ,  Hisashi Sumida ,  Sayaka Kurobuchi ,  Takayuki Matsuda ,  Yuichiro Watanabe ,  Takashi Enomoto ,  Kimiyuki Shibuya ,  Sumiko Kurobuchi

IPC: A61K31/551 ,  C07D401/14 ,  C07D403/06 ,  C07D407/14 ,  A61P3/10 ,  A61P25/28 ,  A61P3/06 ,  A61P29/00 ,  A61K31/496 ,  A61P7/00 ,  A61P9/10 ,  A61P17/00

CPC classification number: C07D233/78 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D405/04 ,  C07D405/14 ,  C07D491/04

Abstract: [Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.[Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)

Abstract translation: [对象]提供一个新颖的LXR＆bgr; 可用作动脉粥样硬化的预防和/或治疗剂的激动剂; 动脉硬化，如糖尿病引起的; 血脂异常 高胆固醇血症 脂质相关疾病; 由炎性细胞因子引起的炎性疾病; 皮肤病如过敏性皮肤病; 糖尿病; 或阿尔茨海默病。 [解决方案]由以下通式（I）表示的甲醇化合物或其盐或其溶剂化物：（其中，V和W各自独立地表示N或C-R7; X和Y各自独立地表示CH 2，C = O ，SO2等; Z表示CH或N;每个R1，R2和R7独立地表示氢原子，C1-8烷基等; R3表示C1-8烷基; R4表示任选取代的C6-10芳基 或任选取代的5至11元杂环基; R 5和R 6表示氢原子等; L表示任选被氧代基等取代的C 1-8烷基链; n表示0〜 2.）

公开(公告)号：US07780292B2

公开(公告)日：2010-08-24

申请号：US11599261

申请日：2006-11-10

Applicant: Atsushi Kakuuchi ,  Kazunori Matsumura ,  Takayoshi Suzuki ,  Yutaka Mizukusa ,  Tadashi Ichihashi

Inventor： Atsushi Kakuuchi ,  Kazunori Matsumura ,  Takayoshi Suzuki ,  Yutaka Mizukusa ,  Tadashi Ichihashi

IPC: A61B3/14 ,  A61B3/10 ,  A61B3/02

CPC classification number: A61B3/12 ,  A61B3/14 ,  A61B3/185

Abstract: An ophthalmologic examination apparatus has a main unit housing an illuminating optical system that illuminates a fundus of a subject's eye to be examined and an imaging optical system that images the illuminated eye fundus. First and second attachment units are removably and exchangeably mounted to the main unit for providing different ophthalmologic functions. The first attachment unit houses an imaging device that captures an image of the eye fundus via the imaging optical system housed in the main unit. The second attachment unit houses a light source that emits stimulating light for an electroretinogram and which is projected onto the eye fundus via the imaging optical system housed in the main unit.

Abstract translation: 眼科检查装置具有容纳照明被检眼睛的眼底的照明光学系统的主体部以及被照射眼底的成像光学系统。 第一和第二附接单元可移除地和可交换地安装到主单元以提供不同的眼科功能。 第一附接单元容纳通过容纳在主单元中的成像光学系统捕获眼底的图像的成像装置。 第二附接单元容纳光源，其发射用于视网膜电图的刺激光，并且经由容纳在主单元中的成像光学系统投射到眼底。

公开(公告)号：US20100184859A1

公开(公告)日：2010-07-22

申请号：US12665342

申请日：2008-06-20

Applicant: Masahiko Ogihara ,  Mitsutoshi Kimura ,  Naoto Ishibashi ,  Jun Kojima

Inventor： Masahiko Ogihara ,  Mitsutoshi Kimura ,  Naoto Ishibashi ,  Jun Kojima

IPC: A61K31/19 ,  A61P1/16

CPC classification number: A61K31/745

Abstract: A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.

Abstract translation: 用于促进肝细胞增殖和肝再生的药物，其包含聚异戊二烯基化合物如3,7,11,15-四甲基-2,4,6,10,14-十六碳五烯酸作为活性成分。

公开(公告)号：US20100149546A1

公开(公告)日：2010-06-17

申请号：US12316358

申请日：2008-12-11

Applicant: Koji Kobayashi ,  Naoki Kobayashi

Inventor： Koji Kobayashi ,  Naoki Kobayashi

IPC: G01B9/02 ,  G01B11/24 ,  H04N7/18

CPC classification number: G01B9/02087 ,  G01B9/02042 ,  G01B9/02091 ,  G01B11/2441 ,  G01B2290/65

Abstract: An optical object measurement apparatus includes a light source for generating a low-coherent light beam, which is swept via an array of pinholes on a Nipkow disk that rotates about an axis. A beam splitter splits the swept light beam into a probe light beam toward an object to be measured and a reference light beam toward a reference optical path. The probe light beam from the object and the reference light that has traveled along the reference optical path are combined in the beam splitter to produce interference light. A two-dimensional image-capturing device detects the interference light and produces a video signal to provide reflection intensity information of the interior of the object. This allows an interference optical system to be readily realized and tomographic images of an object to be observed at high levels of resolution and contrast.

Abstract translation: 光学物体测量装置包括用于产生低相干光束的光源，该光束通过在围绕轴线旋转的Nipkow盘上的针孔阵列扫过。 分束器将扫掠光束分成探针光束朝向被测量物体，并将参考光束朝向基准光路分开。 来自物体的探测光束和沿着参考光路行进的参考光被组合在分束器中以产生干涉光。 二维图像捕获装置检测干涉光并产生视频信号以提供物体内部的反射强度信息。 这允许容易实现干涉光学系统并且以高水平的分辨率和对比度来观察待观察对象的断层图像。